AbbVie Inc. remains in discussions with the White House over drug pricing, according to a Bloomberg report. The company is one of only two major pharmaceutical firms still negotiating.
This update follows Johnson & Johnson’s (J&J) announcement that it reached an agreement with the U.S. government. J&J will lower prices on specific drugs in exchange for an exemption from tariffs.
President Donald Trump initially called on 17 drugmakers to reduce prices. Following the J&J agreement, AbbVie and Regeneron Pharmaceuticals Inc. are the final two companies yet to announce a deal. Both firms previously confirmed they are engaged in White House talks.